Michael Manns

Twincore, Zentrum für Experimentelle und Klinische, is a research institute based in Hannover, Germany. Twincore specializes in translational infection research, with a focus on viral infections, respiratory infections, and organ-specific immunity and metabolism research. The German company also conducts pre-clinical and clinical studies on vaccines and antiviral antibodies. Twincore has an international team of over 40 scientists from more than 20 nations, and the private company places a strong emphasis on international collaboration and exchange programs. The company has organized several symposiums and publishes research papers on various topics related to infection research. The company was founded in 2008, and the CEO is Ulrich Kalinke.

Twincore, Zentrum für Experimentelle und Klinische, is a research institute based in Hannover, Germany. Twincore specializes in translational infection research, with a focus on viral infections, respiratory infections, and organ-specific immunity and metabolism research. The German company also conducts pre-clinical and clinical studies on vaccines and antiviral antibodies. Twincore has an international team of over 40 scientists from more than 20 nations, and the private company places a strong emphasis on international collaboration and exchange programs. The company has organized several symposiums and publishes research papers on various topics related to infection research. The company was founded in 2008, and the CEO is Ulrich Kalinke.

Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.

Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.

Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.

Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.

Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.

Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.

Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.

Twincore, Zentrum für Experimentelle und Klinische, is a research institute based in Hannover, Germany. Twincore specializes in translational infection research, with a focus on viral infections, respiratory infections, and organ-specific immunity and metabolism research. The German company also conducts pre-clinical and clinical studies on vaccines and antiviral antibodies. Twincore has an international team of over 40 scientists from more than 20 nations, and the private company places a strong emphasis on international collaboration and exchange programs. The company has organized several symposiums and publishes research papers on various topics related to infection research. The company was founded in 2008, and the CEO is Ulrich Kalinke.